CardioDynamics, CDIC, Announces Expansion of GE Marquette Medical Systems Strategic Alliance.

Business Editors/Health &Medical Writers

SAN DIEGO--(BW HealthWire)--Feb. 1, 2000

Company's Increased International Presence Results in Orders

from France, Germany, Hong Kong, and China

CardioDynamics International Corp. (Nasdaq:CDIC) manufacturer of BioZ(R) noninvasive digital cardiac output monitoring systems, today announced the expansion of its strategic alliance with GE Marquette Medical Systems. This phase grows the company's distribution by 18 countries, including Russia, Portugal, Turkey, Egypt, Saudi Arabia, United Arab Emirates, and French Speaking Africa.

The expansion of the GE Marquette distribution is important to CardioDynamics as international demand for U.S. medical products is surging. &uot;MediMonitor,&uot; a publication devoted to the latest events in medical equipment markets, recently reported 1999 medical equipment exports are projected to exceed $16.2 billion.

The first phase of the company's strategic alliance with GE Marquette was announced in August 1999, and included distribution rights for CardioDynamics' BioZ Systems in France, Germany, Belgium, Netherlands, and Luxembourg. The second phase followed in October 1999, which provided GE Marquette rights to market and sell the BioZ Systems to hospitals in the United States.

The BioZ Systems are now part of GE Marquette's progressive cardiology management program called CardioIntelligence, which aggregates the critical data used for the comprehensive management of the cardiology patient.

Michael K. Perry, chief executive officer of CardioDynamics, stated, &uot;The expansion of our international distribution with GE Marquette represents another important milestone in the growth of our company. This increased international presence will enable us to aggressively address the projected $16 billion annual medical equipment export market and the growing demand for our BioZ noninvasive heart monitors.&uot;

The company also reported that its increased international presence has resulted in the penetration of international medical markets with sales from several countries, including Hong Kong, China, Germany, and France.

France is one of the top three countries in the world for healthcare spending, with annual expenditures greater than $21 billion. Recently, France's Ministry of Health announced its healthcare expenditures exceeded the growth rate set in its social-security budget. As in the United States, France battles the challenges of treating heart failure, which has become an international healthcare crisis, in part because of the related costs. The number one application for the company's BioZ Systems is in the treatment of heart failure. The French Government recently ordered BioZ Systems for its Military Hospital in Paris.

Perry added, &uot;We are encouraged by the rapid success GE Marquette has experienced in France, as well as the initial overall international acknowledgement of our proprietary ICG technology and its role in improving patient care and reducing costs. The BioZ is especially well-suited for use in countries with socialized medicine, and we look forward to continuing to assist these markets in meeting their needs for cost-effective, safe medical care.&uot;

CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, the BioZ(R) System, BioZ(R) Portable, and BioZ.com(TM), utilize Impedance Cardiography (ICG) to noninvasively obtain data on a wide range of hemodynamic parameters. Whereas Electrocardiography (ECG) measures the heart's electrical characteristics, ICG measures the heart's mechanical (blood flow) characteristics.

Physicians around the world are currently using the BioZ products, including major medical centers such as the Mayo Clinic (Rochester), UCSF Stanford Health Care (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $5 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(R) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1998 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.